Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Thomas J Pittman who wrote (11231)	8/16/1999 5:31:00 PM
From: Dan O	Respond to of 17367

Jack's stmt makes no sense. "I knew the review would take a few weeks and knew we should not go long without saying something" Then he proceeded to say NOTHING.

To: Thomas J Pittman who wrote (11231)	8/16/1999 5:34:00 PM
From: Thomas J Pittman	Read Replies (1) \| Respond to of 17367

.....focus has been on neuprex, but beginning to get a pipeline. Questions: Edmund Dedler (SAC capital) More detail on 'clinical benefit'? A) MUST stick to rules on disclosure. cant say anything. Will you have data at iccaac? Dont know? Sense of strength on numbers?? A) We could but is not in our interest to do so Q) Piper Jaffery What was endpoint prior to first eval A)mortality. in conjunction with FDA we decided to expand it to include morbidity. FDA expressed an interest in these results as well. Q: Was that ethical? A) we are comfortable to have modified the endpoint and still be ethical. Q: q about subpart e Q: when will we hear more A: meeting in october, why so long, they have to have 4 weeks to review